2 Dow Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid

The Dow rose 13% in 2025 and approached 49,000 as the piece highlights three Dow components to watch in 2026: Visa, UnitedHealth Group and Nvidia. Visa is touted as a top buy given its payment-facilitation business, double-digit cross-border volume growth and a forward P/E of 24 (about a 13% discount to its five-year forward average); UnitedHealth is recommended on a turnaround thesis after 2025 headwinds (DOJ probe and Medicare Advantage cost issues), management changes with Stephen Hemsley returning, and a projected 2026 P/E of 19 with potential to restore 2024 EPS of $27.66. Nvidia is flagged as the Dow stock to avoid due to bubble risk, growing in-house competition among large customers and elevated valuation metrics (forward P/E ~25 and a peak P/S near 30, currently ~25). The note also flags macro upside from Fed rate easing (three 25-bp cuts ending 2025) that could lift consumer spending and transaction volumes in 2026.

Analysis

Market structure: Visa (V) and payment processors gain from a prolonged expansion and expected Fed easing — lower rates should lift consumer card spend and cross-border volumes; expect 6–8% annualized TPV growth tailwinds if global travel resumes, pressuring legacy cash/merchant acquirers. UnitedHealth (UNH) is a cyclically reset play: margin recovery from pricing and market exits can restore EPS toward 2024 levels within 4–8 quarters, benefiting Optum’s tech-driven revenue mix. Nvidia (NVDA) sits at the epicenter of demand concentration risk — data-center capex growth is robust but concentrated; a re-pricing shock (P/S sliding from 25 to <15) would materially compress multiples.

Risk assessment: Tail risks include an AI bubble unwind (30–60% downside for NVDA), DOJ penalties or regulatory changes on Medicare Advantage (UNH downside of $2–5/sh EPS hit over 12–24 months), and a sharp consumer pullback that trims Visa volumes by >10% year-over-year. Short-term (days/weeks) volatility will cluster around earnings and regulatory headlines; medium-term (3–12 months) drivers are Fed rate cuts, DOJ probe updates, and hyperscaler product launches; long-term (2–5 years) hinges on structural adoption of AI in healthcare and payment rails. Hidden dependencies: UNH’s optics rely on Optum integration and AI savings that may lag by 2–3 quarters; NVDA’s moat erodes if hyperscalers internalize >20% of incremental GPU demand.

Trade implications: Direct: establish measured long exposure to V (2–4% portfolio) and UNH (2–3%) into any pullbacks over next 3 months; avoid initiating NVDA long exposure above current levels. Pair trades: long UNH vs short NVDA captures value/tech de-risk — target a 1:0.6 size ratio given NVDA’s higher volatility. Options: for NVDA buy 6–9 month 25–35% OTM put spreads sized to cover 20–30% of notional exposure; for V sell 1–3 month cash-secured puts 5–7% OTM to enhance yield if bullish.

Contrarian angles: Consensus dominance of NVDA underestimates hyperscaler substitution and overestimates near-term revenue conversion; a 30% sell-off would likely create a tactical buying window but don’t chase current multiples. The market may underprice Visa’s secular cross-border runway and fee leverage — a durable 24x forward P/E with visible 10%+ TPV growth supports accumulation. For UNH, outcomes hinge on legal clarity: a favorable DOJ resolution or faster Optum AI savings could deliver >20% upside within 12–18 months, so asymmetric risk/reward exists on disciplined entry after any earnings weakness.

Key Decisions for Investors

• Establish a 2–4% long position in Visa (V) over the next 4–8 weeks; if price dips >8% from current levels, add to reach upper allocation. Rationale: durable TPV growth and positive Fed easing macro; target 12–18% upside in 12 months.
• Initiate a 2–3% long position in UnitedHealth Group (UNH) on any 5–12% post-earnings weakness within the next 3 months; size incremental buys if DOJ disclosures signal progress or Optum AI contract wins materialize. Target EPS recovery to $27+ in 12–24 months and 20% upside if margins normalize.
• Avoid new NVDA (NVDA) longs at current multiples; instead, buy a 6–9 month put spread (e.g., 25%/35% OTM) sized to hedge 20–30% of notional tech exposure, or establish a short NVDA position equal to 0.5–1% of portfolio if conviction on valuation correction is high. Consider covering or reversing only if P/S falls below 18 or NVDA declines >30%.
• Execute a pair trade: long UNH (2%) / short NVDA (1.2%) to capture value rotation over 6–12 months, rebalancing monthly and trimming positions if UNH misses margin improvement guidance or NVDA reports unexpected product-led demand persistence.
• Use options to enhance yield: sell 1–3 month cash-secured puts on V 5–7% OTM (size 1–2% of portfolio) to generate income while accumulating shares at cheaper levels; close if implied volatility jumps >40%.